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SAGA et Al. adapted to the stage and grade of the individual prostate cancer case. 3 Medical imaging is expected to play an important role in the characterization of prostate cancer for personalized medicine. 4 Recently, prostate-specific membrane antigen (PSMA) has received attention as a target of imaging and therapy for prostate cancer. 5 Prostate-specific membrane antigen is a cell-surface enzyme also known as glutamate carboxypeptidase II or folate hydrolase. 6 It is overexpressed on most prostate cancer cells and its expression increases in higher grade cancers and in metastatic and recurrent cancers. 7, 8 Furthermore, the level of PSMA expression is correlated with prognosis. 9 Although PSMA is physiologically expressed in normal tissues such as the proximal renal tubules, salivary/lachrymal glands, and small intestine, and on neo-vasculatures of some cancers such as renal cancer, 10 normal prostate tissue expresses only a small amount in the apical epithelium of the secretory ducts. 8 Therefore, PSMA is regarded as an optimal imaging and therapy target in prostate cancer.
Although PSMA-targeted imaging in prostate cancer was initially carried out using radiolabeled anti-PSMA Abs, the use of radiolabeled small molecular weight PSMA inhibitors is becoming more popular. 11, 12 The clinical utility of PET/computed tomography (CT) using 68 Ga-labeled PSMA inhibitors, such as 68 Ga-PSMA-11, which is the most widely used inhibitor, has been reported in many papers. 13, 14 Recently, 18 F-labeled PSMA inhibitors have also been developed and used clinically. 15, 16 Furthermore, PSMA inhibitors labeled with the β-emitter, 177 Lu, and the α-emitter, 225 Ac, have been introduced for PSMA-targeted radioligand therapy and have yielded promising therapeutic results. 12, 17, 18 Despite the worldwide application of PSMA-targeted ligands in the imaging and treatment of prostate cancer, prostate cancer patients in Japan are unable to benefit from these PSMA-targeted probes.
Recently, a small molecule PET probe based on a PSMA-inhibitor labeled with 18 F has been developed at our institution. 19 Preclinical studies indicated that this PET probe, named 18 F-FSU-880, possesses a high binding affinity for PSMA and shows a favorable pharmacokinetic profile with high accumulation in PSMA-expressing tumors. 19 The present first-in-man study was undertaken to evaluate the safety, whole-body distribution, dose estimation, and lesion accumulation of 18 F-FSU-880. PET/CT, blood and urine samples were collected from the patients and analyzed for safety evaluation.
| MATERIAL S AND ME THODS

| 18 F-FSU-880 PET/CT
18 F-FSU-880 ( Figure 1 ) was prepared on a COSMiC-Compact 24XX automated synthesis module (NMP Business Support Company, Chiba, Japan), following previously published methods, 19 and was filter-sterilized.
The PET/CT studies were carried out using an integrated PET/ CT scanner (Discovery IQ; GE Healthcare, Waukesha, WI, USA) with a bismuth germanate scintillator arranged in five rings and a 16-detector-row CT scanner. Patients fasted for >4 hours before their study. After evaluating the vital signs of the patients (blood pressure, heart rate, and respiration rate), low-dose CT was carried out for attenuation correction and for image fusion without oral/i.v.
contrast. 18 F-FSU-880 (115.4-180.3 MBq) was then slowly given i.v.
Whole-body emission data acquisition commenced 30 seconds after injection of 18 F-FSU-880 and was repeated 4 times. Emission data were acquired in 3D mode starting from the femur to the skull. The first and second scans (PET 1 and PET 2, respectively) consisted of 1 minute/frame × 6 frames, and the third and fourth scans (PET 3 and PET 4, respectively) consisted of 2 minute/frame × 6 frames.
After PET 4, patients were asked to void for the radioactivity measurement of the urine. The final scan (PET 5) was undertaken 2 hours after administration of 18 F-FSU-880. The vital signs were evaluated again after PET 5.
During PET/CT, blood samples were collected four times (immediately after starting PET 1, and at the end of PET 2, PET 4, and PET 5), and the radioactivity of the whole blood and plasma was evaluated.
| Image analysis
Images of the whole body from the skull to the femur were reconstructed using an ordered subset expectation maximization algorithm (subsets, 14; iteration, 2) with CT-attenuation correction. Point spread function correction was also carried out.
The PET/CT images were visually reviewed on a workstation (Advantage Workstation 4.6; GE Healthcare) by 2 board-certified nuclear medicine physicians (TS and YN), who were not blinded to were obtained. The VOIs were reproduced on the PET 1 to PET 4 images for SUV evaluation. Tumor-to-blood ratios (TBRs) were also calculated by dividing the lesion SUVmax by the SUVmean of blood pool (heart content) of the corresponding PET series.
| Radioactivity in blood and urine
Collected blood was divided into whole blood and plasma samples.
Both samples were weighed and counted for radioactivity using a well-type γ-counter. Urine samples were measured for volume and the radioactivity was counted. All count data were decay-corrected and adjusted at the time of probe administration.
| Radiation dosimetry
The 
| RE SULTS
| Demographics
Six prostate cancer patients with known metastatic lesions were included in the present study ( Table 1 ). The serum prostate-specific antigen (PSA) values at the time of PET/CT ranged from 0.01 to 8.72 ng/mL. Five patients were known to have bone metastases by CT and/or bone scintigraphy and the remaining 1 patient had lymph node (LN) metastasis detected by CT.
| Safety
Administration of 
| Whole-body distribution and dose estimation
Whole-body maximal intensity projection images of PET 1 to PET 5 in case 6 are illustrated in Figure 2A spleen, kidney, and heart content) in case 6 is presented in Figure 2B . Radioactivity counting in the whole blood and plasma indicated that >88.5% (range, 88.5%-98.3%) radioactivity was detected in the plasma fraction. The change in blood activity derived from the VOI/ SUV analysis of the heart content was mostly comparable with that derived from γ-counting of whole blood activity (data not shown).
Urine collected between PET 4 and PET 5 was assessed for radioactivity, and the results indicated that 8.0%-13.2% of total radioactivity was excreted into the urine.
Dosimetry analyses were applied using the PET SUV data and OLINDA/EXM software. The results are summarized in 
| Lesion accumulation of 18 F-FSU-880
In 5 of 6 patients, known metastatic lesions were clearly visualized with SUVmax and image contrast (TBRs), which increased with time (Table 3) . Larger lesions tended to show very high uptake of 18 F-FSU-880 and very high TBRs. Furthermore, additional abnormally increased uptakes were detected in 3 patients: recurrent lesion in the prostate was suspected in case 1 (Figure 3) , additional LN metastasis in case 2, and multiple bone metastases in case 4 ( Figure 4 ).
In case 5, the 18 F-FSU-880 uptake in known bone metastases remained low at all time points and did not increase with time, resulting in poor lesion-to-background contrast (TBR < 1 in all PET series).
| D ISCUSS I ON
18 F-FSU-880 is a newly developed small molecule PET probe that targets PSMA. 19 18 F-FSU-880 has an asymmetric urea compound that acts as a binding moiety for PSMA, which is common among various radiolabeled PSMA-targeting probes ( Figure 1 ). The structureactivity relationship was previously determined in an 123 I-labeled asymmetric urea compound and indicated that the aromatic ring and succinimidyl moiety are associated with high binding affinity. 19 We therefore selected 18 F-10a for clinical evaluation and renamed it 18 F-FSU-880.
In the present first-in-man clinical study, administration of 18 F-FSU-880 could be carried out safely without the occurrence of significant adverse events. Although changes in blood analyses data were observed in 4 of 6 patients, the grade of the changes was minimal, and the values returned to within the normal range in all cases in the follow-up examinations without any clinical intervention. These changes could therefore be regarded to be within the range of physiological fluctuations and insignificant as adverse effects. In addition, no clinical events or data were observed suggesting late phase adverse effects. Case 1 suffered ACNA-associated vasculitis, which was likely to be independent to 18 among other small molecule PSMA inhibitors. The high uptake of 18 F-FSU-880 observed in the kidneys and salivary and lachrymal glands might reflect physiological PSMA expression in these organs. However, the reported PSMA expression in the salivary glands was rather low compared to the observed high probe uptake, and radiolabeled anti-PSMA Ab did not show high salivary gland uptake, 22, 23 indicating that some additional mechanism related to the small molecular size should be considered. 24 Although a preclinical study had shown that 18 F-FSU-880 is excreted exclusively from the kidneys, 19 the amount of 18 F-FSU-880 excreted into urine during the PET 4/PET 5 interval was relatively low (8.0%-13.2%), suggesting that more rigid hydration to accelerate diuresis would be beneficial in future studies to further reduce background activity and improve image contrast.
The organ dose calculation indicated that the kidneys received the highest dose, followed by the liver. However, renal dose is ex- The effect of treatment on the uptake of PSMA-targeted probe is not fully elucidated yet. Short-term androgen deprivation therapy has been reported to increase PSMA expression in castrationsensitive PC cells, 29 and long-term androgen deprivation therapy is reported to reduce the visibility of the lesions. 30 In the present patient cohort, cases 1 and 2 received PET/CT with no treatment. With the increasing number of patients examined with PSMAtargeted probes, many pitfalls are emerging. 31 In this study, we ex- 
